Generation Bio Co. (NASDAQ:GBIO) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Generation Bio Co. (NASDAQ:GBIO) have earned an average recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.8750.

Several research firms recently weighed in on GBIO. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Generation Bio in a report on Friday, November 7th. Wedbush set a $5.50 price objective on Generation Bio and gave the company an “outperform” rating in a report on Tuesday, December 16th. Jefferies Financial Group downgraded Generation Bio from a “buy” rating to a “hold” rating and dropped their target price for the stock from $11.00 to $5.00 in a report on Tuesday, December 16th. Citigroup reissued a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research note on Wednesday, October 8th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GBIO. Cantor Fitzgerald L. P. bought a new stake in shares of Generation Bio in the third quarter valued at approximately $606,000. ADAR1 Capital Management LLC acquired a new position in Generation Bio in the 3rd quarter valued at $136,000. Shay Capital LLC acquired a new position in Generation Bio in the 3rd quarter valued at $64,000. Militia Capital Partners LP bought a new stake in shares of Generation Bio during the 2nd quarter valued at $174,000. Finally, Marshall Wace LLP bought a new stake in shares of Generation Bio during the 2nd quarter valued at $37,000. 95.22% of the stock is owned by institutional investors.

Generation Bio Stock Performance

Shares of GBIO stock opened at $5.48 on Friday. Generation Bio has a 52 week low of $3.00 and a 52 week high of $10.40. The company has a market capitalization of $36.94 million, a price-to-earnings ratio of -0.59 and a beta of 2.05. The company has a 50-day simple moving average of $5.38 and a 200 day simple moving average of $5.34.

Generation Bio (NASDAQ:GBIO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.18) by $2.36. Generation Bio had a negative net margin of 410.13% and a negative return on equity of 94.82%. The firm had revenue of $1.59 million during the quarter, compared to the consensus estimate of $0.66 million. Sell-side analysts forecast that Generation Bio will post -1.75 EPS for the current year.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.